FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression

NCT02325739 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

172

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)
Solid Malignancies

Interventions

DRUG: FGF401
BIOLOGICAL: PDR001

Sponsor

Novartis Pharmaceuticals